Prot #CPDR001XUS01: Modular Phase 2 Study to Link Combination Immune-Therapy to Patients with Advanced Solid and Hematologic Malignancies Module 9: PDR001 Plus LAG525 for Patients with Advanced Solid and Hematologic Malignancies

Project: Research project

Project Details

StatusFinished
Effective start/end date2/23/18 → 2/28/21

Funding

  • United BioSource LLC (Prot #CPDR001XUS01 // Prot #CPDR001XUS01)
  • Novartis Pharmaceuticals Corporation (Prot #CPDR001XUS01 // Prot #CPDR001XUS01)